Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...
Hanmi Pharmaceutical's Global Business Headquarters Overseas Sales Team is making significant strides in penetrating the ...
Aytu BioPharma reported a decrease in net revenue for Q2 2025, reflecting challenges in its ADHD portfolio. Despite this, the company posted a net income of $800,000, translating to $0.13 per share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback